-
Je něco špatně v tomto záznamu ?
Haloperidol and aripiprazole impact on the BDNF and glucocorticoid receptor levels in the rat hippocampus and prefrontal cortex: effect of the chronic mild stress
J. Osacka, R. Koprdova, A. Tillinger, Z. Pirnik, A. Kiss
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2016
Free Medical Journals
od 2016
ProQuest Central
od 2016-01-01
Sciendo
od 2016-03-30
ROAD: Directory of Open Access Scholarly Resources
od 1998
PubMed
34523299
DOI
10.2478/enr-2021-0016
Knihovny.cz E-zdroje
- MeSH
- antipsychotika * farmakologie MeSH
- aripiprazol farmakologie MeSH
- haloperidol * MeSH
- hipokampus MeSH
- krysa rodu rattus MeSH
- mozkový neurotrofický faktor genetika MeSH
- prefrontální mozková kůra MeSH
- receptory glukokortikoidů genetika MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Objective. Changes in the brain derived neurotrophic factor (BDNF) and glucocorticoid receptor (GR) expression in the prefrontal cortex (PFC) and hippocampus (HIP) are associated with psychiatric diseases and stress response. Chronic mild stress (CMS) may alter BDNF as well as GR levels in both the PFC and the HIP. The aim of the present study was to find out whether chronic treatment with a typical antipsychotic haloperidol (HAL) and an atypical antipsychotic aripiprazole (ARI) may modify the CMS effect on the BDNF and GR expression in the above-mentioned structures. Methods. The rats were exposed to CMS for 3 weeks and from the 7th day of CMS injected with vehicle (VEH), HAL (1 mg/kg) or ARI (10 mg/kg) for 4 weeks. BDNF and GR mRNA levels were established in the PFC and the HIP by Real Time PCR, whereas, PFC and HIP samples were obtained by punching them from 500 μm thick frozen sections. C-Fos immunoreactivity was analyzed in the PFC and the HIP on 30 μm thick paraformaldehyde fixed sections. Weight gain and corticosterone (CORT) levels were also measured. Results. The CMS and HAL suppressed the BDNF and GR mRNA levels in the PFC. In the HIP, CMS elevated BDNF mRNA levels that were suppressed by HAL and ARI treatments. The CMS decreased the c-Fos immunoreactivity in the PFC in both HAL- and ARI-treated animals. In the HIP, HAL increased the c-Fos immunoreactivity that was again diminished in animals exposed to CMS. Stressed animals gained markedly less weight until the 7th day of CMS, however, later their weight gain did not differ from the unstressed ones or was even higher in CMS+HAL group. Un-stressed HAL and ARI animals gained less weight than the VEH ones. Neither CMS nor HAL/ARI affected the plasma CORT levels. Conclusion. The present data indicate that HAL and ARI in the doses 1 mg/kg or 10 mg/kg, respectively, does not modify the effect of the CMS preconditioning on the BDNF and GR mRNA levels in the PFC or the HIP. However, HAL seems to modify the CMS effect on the HIP activation.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012214
- 003
- CZ-PrNML
- 005
- 20220506125850.0
- 007
- ta
- 008
- 220425s2021 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2478/enr-2021-0016 $2 doi
- 035 __
- $a (PubMed)34523299
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Osacka, Jana $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia
- 245 10
- $a Haloperidol and aripiprazole impact on the BDNF and glucocorticoid receptor levels in the rat hippocampus and prefrontal cortex: effect of the chronic mild stress / $c J. Osacka, R. Koprdova, A. Tillinger, Z. Pirnik, A. Kiss
- 520 9_
- $a Objective. Changes in the brain derived neurotrophic factor (BDNF) and glucocorticoid receptor (GR) expression in the prefrontal cortex (PFC) and hippocampus (HIP) are associated with psychiatric diseases and stress response. Chronic mild stress (CMS) may alter BDNF as well as GR levels in both the PFC and the HIP. The aim of the present study was to find out whether chronic treatment with a typical antipsychotic haloperidol (HAL) and an atypical antipsychotic aripiprazole (ARI) may modify the CMS effect on the BDNF and GR expression in the above-mentioned structures. Methods. The rats were exposed to CMS for 3 weeks and from the 7th day of CMS injected with vehicle (VEH), HAL (1 mg/kg) or ARI (10 mg/kg) for 4 weeks. BDNF and GR mRNA levels were established in the PFC and the HIP by Real Time PCR, whereas, PFC and HIP samples were obtained by punching them from 500 μm thick frozen sections. C-Fos immunoreactivity was analyzed in the PFC and the HIP on 30 μm thick paraformaldehyde fixed sections. Weight gain and corticosterone (CORT) levels were also measured. Results. The CMS and HAL suppressed the BDNF and GR mRNA levels in the PFC. In the HIP, CMS elevated BDNF mRNA levels that were suppressed by HAL and ARI treatments. The CMS decreased the c-Fos immunoreactivity in the PFC in both HAL- and ARI-treated animals. In the HIP, HAL increased the c-Fos immunoreactivity that was again diminished in animals exposed to CMS. Stressed animals gained markedly less weight until the 7th day of CMS, however, later their weight gain did not differ from the unstressed ones or was even higher in CMS+HAL group. Un-stressed HAL and ARI animals gained less weight than the VEH ones. Neither CMS nor HAL/ARI affected the plasma CORT levels. Conclusion. The present data indicate that HAL and ARI in the doses 1 mg/kg or 10 mg/kg, respectively, does not modify the effect of the CMS preconditioning on the BDNF and GR mRNA levels in the PFC or the HIP. However, HAL seems to modify the CMS effect on the HIP activation.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a antipsychotika $x farmakologie $7 D014150
- 650 _2
- $a aripiprazol $x farmakologie $7 D000068180
- 650 _2
- $a mozkový neurotrofický faktor $x genetika $7 D019208
- 650 12
- $a haloperidol $7 D006220
- 650 _2
- $a hipokampus $7 D006624
- 650 _2
- $a prefrontální mozková kůra $7 D017397
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a receptory glukokortikoidů $x genetika $7 D011965
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Koprdova, Romana $u Institute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovak Republic
- 700 1_
- $a Tillinger, Andrej $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia
- 700 1_
- $a Pirnik, Zdenko $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia $u Institute of Physiology, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovak Republic $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Kiss, Alexander $u Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia
- 773 0_
- $w MED00001518 $t Endocrine regulations $x 1336-0329 $g Roč. 55, č. 3 (2021), s. 153-162
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34523299 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506125842 $b ABA008
- 999 __
- $a ok $b bmc $g 1789698 $s 1163415
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 55 $c 3 $d 153-162 $e 20210913 $i 1336-0329 $m Endocrine regulations $n Endocr. Regul. $x MED00001518
- LZP __
- $a Pubmed-20220425